FY2025 Earnings Forecast for ABUS Issued By Chardan Capital

Arbutus Biopharma Co. (NASDAQ:ABUS) – Analysts at Chardan Capital lowered their FY2025 EPS estimates for shares of Arbutus Biopharma in a research note issued on Tuesday, March 4th. Chardan Capital analyst K. Nakae now expects that the biopharmaceutical company will post earnings per share of ($0.38) for the year, down from their previous estimate of ($0.30). Chardan Capital has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Arbutus Biopharma’s current full-year earnings is ($0.39) per share. Chardan Capital also issued estimates for Arbutus Biopharma’s FY2026 earnings at ($0.30) EPS.

ABUS has been the topic of a number of other reports. StockNews.com upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Arbutus Biopharma in a report on Tuesday, January 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Arbutus Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Arbutus Biopharma Trading Down 1.8 %

Shares of NASDAQ:ABUS opened at $3.31 on Friday. The stock’s fifty day simple moving average is $3.34 and its two-hundred day simple moving average is $3.64. Arbutus Biopharma has a 1-year low of $2.30 and a 1-year high of $4.73. The stock has a market cap of $627.22 million, a PE ratio of -7.70 and a beta of 1.93.

Institutional Investors Weigh In On Arbutus Biopharma

Several institutional investors have recently modified their holdings of ABUS. Creative Planning lifted its holdings in Arbutus Biopharma by 13.8% in the third quarter. Creative Planning now owns 49,500 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 5,989 shares during the period. Intech Investment Management LLC bought a new position in Arbutus Biopharma in the third quarter valued at about $142,000. Charles Schwab Investment Management Inc. lifted its holdings in Arbutus Biopharma by 218.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company’s stock valued at $4,667,000 after acquiring an additional 831,663 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Arbutus Biopharma by 453.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 30,723 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Arbutus Biopharma in the third quarter valued at about $754,000. 43.79% of the stock is owned by hedge funds and other institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.